-

Viz.ai Named One of the World’s Most Innovative Companies by Fast Company Magazine

Viz.ai joins the ranks of distinguished businesses that are paving the way for innovations of tomorrow on Fast Company’s World’s Most Innovative Companies list for 2024

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has been named to Fast Company’s Most Innovative Companies for 2024. The prestigious annual list recognizes the world’s most groundbreaking companies at the forefront of their respective industries. Viz.ai was chosen from renowned companies across the globe for this list, which is widely recognized as a preeminent honor a business may receive for its novel ideas or approach to radically transform an industry or sector.

“This award speaks volumes about the real-world impact we have already made toward improving patient outcomes with our innovative approach to harnessing the power of artificial intelligence,” said Chris Mansi, MD, CEO and co-founder at Viz.ai. “Our AI-powered care coordination solution is leading the charge to streamline the way patient care is delivered, provide relevant clinical insights, and inform critical decisions at the point of care. We are honored to be recognized as one of the World’s Most Innovative Companies by Fast Company and look forward to continuing to drive meaningful change in healthcare and life sciences by improving patient access to life-saving treatments and outcomes.”

Viz.ai develops and deploys its Viz.ai One platform across its vast footprint to streamline patient journeys and accelerate speed to diagnosis and therapy. Viz.ai was granted the first de novo approval by the FDA for AI computer-aided triage in 2018 and again in 2023 for cardiovascular machine learning-based notification software. In January 2024, the company surpassed adoption in 1,500 hospitals in the United States, including the majority of the 50 largest healthcare systems. It also works with 7 of the top 30 global life science companies.

Viz.ai One integrates with electronic health records (EHRs) and radiology worklist systems to empower multidisciplinary care teams and help coordinate care across workflows. With more than 100 clinical abstracts and publications, Viz.ai continues to demonstrate significant real-world evidence on the patient and economic outcomes of AI-powered care coordination.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Media Contact
Olivia Schlabach
olivia.schlabach@finnpartners.com

Viz.ai


Release Versions

Contacts

Media Contact
Olivia Schlabach
olivia.schlabach@finnpartners.com

Social Media Profiles
More News From Viz.ai

A Decade of Increasing Access to Life Saving Treatments: Viz.ai Celebrates 10 Years, 2,000 Hospitals, and 230 Million Patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing tr...

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to pote...

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...
Back to Newsroom